Results 51 to 60 of about 115,960 (309)

Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group

Haematologica, 2011
Background Optimal lymphocyte parameters and thresholds for the diagnosis of chronic lymphocytic leukemia have been proposed by The National Cancer Institute sponsored Working Group and recently updated by the International Workshop on chronic ...
Stefano Molica, Francesca R. Mauro, Diana Giannarelli, Francesco Lauria, Agostino Cortelezzi, Maura Brugiatelli, Vincenzo Liso, Antonio Cuneo, Robin Foà   +8 more
doaj   +1 more source

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia : implication for therapy [PDF]

This work was supported by: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 x mille n.9980, (to M.F., F.M. A. N., P.T. and M.N.) ; AIRC I.G. n. 14326 (to M.F.), n.10136 and 16722 (A.N.), n.15426 (to F.F.).
Baio, G., Basso, L., Boccardo, S., Calabrese, M., Cilli, M., Colombo, M., Cutrona, G., Emionite, L., Fabris, S., Fais, F., Ferrarini, M., Gentile, M., Massara, R ., Massucco, C., Matis, S., Morabito, F., Negrini, M., Neri, A., Neumaier, C. E., Recchia, A. G., Reverberi, D., Rosa, F., Salvi, S., Tassone, P., Truini, M., Valdora, F., Zupo, S.   +26 more
core   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia

Haematologica, 2013
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were
Davide Brusa, Sara Serra, Marta Coscia, Davide Rossi, Giovanni D’Arena, Luca Laurenti, Ozren Jaksic, Giorgio Fedele, Giorgio Inghirami, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio   +11 more
doaj   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, EarlyView.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy

Haematologica, 2014
Biologists and clinicians agree that the B-cell receptor influences the behavior of chronic lymphocytic leukemia, and promising new drugs are aimed at receptor-associated kinases.
Graham Packham, Serge Krysov, Alex Allen, Natalia Savelyeva, Andrew J. Steele, Francesco Forconi, Freda K. Stevenson   +6 more
doaj   +1 more source

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]

Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E, Carvajal, T, Castro, JE, Chang, J, Choi, MY, James, DF, Kipps, TJ   +6 more
core   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones

Haematologica, 2014
In chronic lymphocytic leukemia, usually a monoclonal disease, multiple productive immunoglobulin heavy chain gene rearrangements are identified sporadically. Prognostication of such cases based on immunoglobulin heavy variable gene mutational status can
Karla Plevova, Hana Skuhrova Francova, Katerina Burckova, Yvona Brychtova, Michael Doubek, Sarka Pavlova, Jitka Malcikova, Jiri Mayer, Boris Tichy, Sarka Pospisilova   +9 more
doaj   +1 more source

Bullous leukemia cutis mimicking facial cellulitis [PDF]

Anais Brasileiros de Dermatologia, 2016
Bullous leukemia cutis is an uncommon clinical manifestation of cutaneous infiltration by leukemic cells, from B-cell chronic lymphocytic leukemia. We present the case of a 67-year-old, female, chronic lymphocytic leukemia patient.
Luciana de Sales Caldato, Juliana de Sousa Britto, Ligia Niero-Melo, Hélio Amante Miot   +3 more
doaj   +1 more source